August 13, 2020

Newer targeted therapy prolongs life for lung cancer patients

Patients with ALK-positive non-small cell lung cancer treated with ensartinib fared better and lived longer than those who received crizotinib, according to results of a phase 3 study.

By Tom Wilemon